1. A novel STING agonist for cancer immunotherapy and a SARS-CoV-2 vaccine adjuvant.
- Author
-
Wu, Jun-Jun, Zhao, Lang, Han, Bei-Bei, Hu, Hong-Guo, Zhang, Bo-Dou, Li, Wen-Hao, Chen, Yong-Xiang, and Li, Yan-Mei
- Subjects
SARS-CoV-2 ,IMMUNOTHERAPY ,ANTIBODY titer ,ALUMINUM hydroxide ,TUMOR microenvironment - Abstract
A novel STING agonist, CDG
SF , ipsilaterally modified with phosphorothioate and fluorine, was synthesized. The phosphorothioate in CDGSF might be a site for covalent conjugation. Injection of CDGSF generated an immunogenic ("hot") tumor microenvironment to suppress melanoma, more efficiently than dithio CDG. In particular, immunization with SARS-CoV-2 spike protein using CDGSF as an adjuvant elicited an exceptionally high antibody titer and a robust T cell response, overcoming the drawbacks of aluminum hydroxide. These results highlighted the therapeutic potential of CDGSF for cancer immunotherapy and the adjuvant potential of the STING agonist in the SARS-CoV-2 vaccine for the first time. [ABSTRACT FROM AUTHOR]- Published
- 2021
- Full Text
- View/download PDF